The adenoviral oncogene E1A-13S interacts with a specific isoform of the tumor suppressor PML to enhance viral transcription

Julia Berscheminski1, Peter Groitl1, Thomas Dobner1**, Peter Wimmer1* and Sabrina Schreiner1*

*These authors contributed equally to this project and should be considered as co-last authors

1 Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Martinistr. 52, 20251 Hamburg, Germany

**Corresponding author Phone: +49 40 48051 301 Fax: +49 40 48051 302 Email: thomas.dobner@hpi.uni-hamburg.de

Running title: Ad5 E1A interacts with PML-II

Keywords: human adenovirus/ E1A/ PML isoforms/ transcription/ gene expression/PML-NBs/ viral oncogene

Word count in Abstract: 236
Word count in Manuscript: 7958
Abstract

PML-NBs, also called ND10 are matrix-bound nuclear structures that have been implicated in a variety of functions, including DNA repair, transcriptional regulation, protein degradation, and tumor suppression. These domains are also known for their potential to mediate an intracellular defense mechanism against many virus types. This is likely why they are targeted and subsequently manipulated by numerous viral proteins. Paradoxically the genomes of various DNA viruses become associated with PML-NBs, and initial sites of viral transcription/replication centers are often juxtaposed to these domains. The question is why viruses start their transcription and replication next to their supposed antagonists. Here, we report that PML-NBs are targeted by the adenoviral (Ad) transactivator protein E1A-13S. Alternatively spliced E1A isoforms (E1A-12S and E1A-13S) are the first proteins expressed upon Ad infection. E1A-13S is essential for activating viral transcription in the early phase of infection. Co-immunoprecipitation assays showed that E1A-13S preferentially interacts with only one (PML-II) of at least six nuclear human PML isoforms. Deletion mapping located the interaction site within the E1A CR3, previously described as the transcription factor binding region of E1A-13S. Indeed, cooperation with PML-II enhanced E1A-mediated transcriptional activation, while deleting the SIM of PML proved even more effective. Our results suggest that contrary to PML-NB-associated anti-viral defense, PML-II may help transactivate viral gene expression, and therefore play a novel role in activating Ad transcription during the early viral life cycle.
Human Adenovirus type 5 E1A (early region 1A) is the first protein expressed upon infection, and plays an essential role in transcriptional activation and induction of cell cycle progression (24). In early times of infection two major E1A proteins, E1A-12S (243R) and E1A-13S (289R), are synthesized from alternatively spliced mRNA transcripts of the E1A gene (10, 72). The proteins are identical except for an 46 amino acid (aa) long conserved region (CR3) unique to the larger E1A protein (72). Despite being very similar, these proteins show significant differences in their biological activities. The larger E1A isoform (E1A-13S) is considered to be primarily responsible for transactivating viral gene expression by interacting with a wide range of transcription factors via its CR3 (35, 47, 57, 67, 87).

The PML (promyelocytic leukemia) protein was first described in acute promyelocytic leukemia (APL), showing that PML was fused to the retinoic acid receptor alpha (RARα) due to a chromosomal translocation (t15;17) (3, 9, 14, 18, 28, 43, 44, 46, 61, 62, 68, 98). The PML gene encodes multiple isoforms, derived from alternative mRNA splicing, differing only in the C-terminal part of the proteins (41). PML seems to be responsible for the assembly of nuclear bodies by recruiting other constitutive components such as Daxx (death-domain associated protein), Sp100 (speckled protein of 100 kDa) or SUMO (small ubiquitin-related modifier) (4, 39, 82). Other components such as p53, pRb and CBP/p300 are only present under certain circumstances (summarized in 66). Modification of PML by SUMO is critical for PML-NB (PML nuclear body) formation (39, 106) and SUMOylated proteins, that are often found in PML NBs (81) are recruited to PML NBs by the SIM (SUMO interacting motif) of PML (82).
Since various proteins localize to PML nuclear bodies, these domains have been associated with numerous functions such as protein degradation (48), transcriptional regulation (54, 107), cellular senescence (6, 23, 50, 69), tumor suppression (76, 77), DNA repair (5, 7), apoptosis (36, 88) and epigenetic regulation (91).

PML itself is a member of the RING finger family of proteins, including proteins mainly involved in transcriptional regulation. Although PML does not exhibit DNA binding activity, its RBCC domain displays RING finger-dependent transactivating activity (1). Indeed, PML has been found to act both as a transcriptional co-activator (32, 94) and co-repressor (2, 93). It is thought to regulate transcription through targeting various DNA binding transcription factors/cofactors such as CBP/p300 and nuclear receptor cofactor TIF1α (16, 94, 105, 107).

PML and PML-associated factors are suspected to mediate intracellular, anti-viral defense mechanisms, and are therefore targeted by multiple viral proteins during infection (21, 22, 90). Interestingly, genomes of human DNA viruses such as adenoviruses, herpesviruses, polyomaviruses, and papillomaviruses associate with PML-NB components at initial stages in their replication cycles (15, 21, 38, 42, 59, 60).

Consequently, newly formed transcription and replication sites are often found juxtaposed to the PML nuclear domains (86).

In our present study, we further clarify the relationship between adenoviral proteins and PML nuclear structures, and have analyzed of the role of PML during productive adenoviral infection with respect to functional cooperation with specific E1A variants. We show that E1A-13S interacts with the PML-II isoform through the CR3 (conserved region 3) of E1A, and together this complex elevates transcription from adenoviral E2 early promoter. Mutation of the SUMO interacting motif in PML-II
further enhanced this E1A-dependent transactivation. Furthermore, PML-II combined with E1A-13S stimulated cellular gene expression through interacting with cellular transcriptional co-activator p300, suggesting adenovirus takes advantage of PML and associated factors to regulate cellular as well as viral transcription.
**Materials and Methods**

**Cell lines.**

HepaRG (30), HALP/HALP PML-II cells (11), H1299 (63) and mouse embryonic fibroblasts (MEF) (96) were grown in DMEM supplemented with 10% FCS, 100 U of penicillin, 100 µg of streptomycin per ml in a 5% CO₂ atmosphere at 37°C. For HepaRG cells the medium was additionally supplemented with 5 µg/ml of bovine insulin and 0.5 µM of hydrocortisone.

**Plasmids and transient transfections.**

Ad5 E1A-12S, Ad5 E1A-13S and the Ad5 E1A mutant proteins were expressed from pcDNA3 vector. N-terminal flag-tagged human PML-isoforms I-VI were expressed from the pLKO.1-puro vector and kindly provided from Roger Everett (Glasgow). All PML-isoforms are named according to the nomenclature of Jensen et al. (41) as PML-I (AAG50180), PML-II (AF230410), PML-III (S50913), PML-IV (AAG50185), PML-V (AAG50181) and PML-VI (AAG50184). PML-II-SIM mutation was introduced by site-directed mutagenesis using oligonucleotides (fwd primer 5´-GGAACGCGGTGGGGGGATCAGCAGC-3' and rev primer 5'-GCTGCTGATCCCCCCACCGCGTTCC-3', see also Fig. 8A). For transient transfection, subconfluent cells were treated with a mixture of DNA and 25 kDa linear polyethylenimine (Polysciences) as described previously (64).

**Viruses.**

H5pg4100 served as wild type virus (31). H5dl347 and H5dl348 carry cloned segments corresponding to E1A-12S and E1A-13S mRNAs, respectively, in place of the E1A
gene. H5dl312 lacks a large segment of the E1A gene and therefore does not produce E1A products (103). H5pm4150 carries a frameshift mutation in the E4orf3 open reading frame and H5pm4149 carries stop codons in the E1B-55K open reading frame so they do not express E4orf3 or E1B-55K, respectively (26, 45). All viruses were propagated and titered as fluorescent forming units in HEK293 monolayer cultures (31). To measure virus growth, infected cells were harvested at 48 h postinfection (p.i.) and lysed by three cycles of freeze-thawing. The cell lysates were serially diluted in DMEM for infection of HEK293 cells, and virus yield was determined by quantitative E2A immunofluorescence staining at 24 h after infection.

**Luciferase reporter assay.**

For dual luciferase assays, subconfluent H1299 cells were transfected as described above, using 1 µg of reporter (pGL C3G5-luc; pGL-E2early-promoter), 1 µg of pRL-TK (*Promega*), which expresses Renilla luciferase under the control of the herpes simplex virus thymidine kinase (HSV-TK) promoter, and 1 µg of effector plasmids (E1A-12S, E1A-13S, PML-II, pG4-p300). Cells extracts were prepared, measured and normalized as described recently (78).

**Antibodies and protein analysis.**

Primary antibodies specific for Ad proteins included E1A mouse monoclonal antibody (mAb) M58 and E1A mouse mAb M73 (34) and E2A mouse mAb B6-8 (75). E1A rabbit mAb 610 was a kind gift of Roger Grand. Primary antibodies specific for cellular and epitopically expressed proteins included PML rabbit pAb NB100-59787 (*Novus Biologicals, Inc.*), PML mouse mAb clone 36.1-104 (*Millipore*), Flag mouse mAb flag-M2 (*Sigma-Aldrich, Inc.*) and β-actin mouse mab AC-15 (*Sigma-Aldrich, Inc.*).
All protein extracts were prepared in RIPA lysis buffer as published recently (101). For immunoprecipitation flag-M2 coupled protein A-sepharose beads (Sigma-Aldrich, Inc.) were used, or protein A sepharose (3 mg/IP) was coupled with 1 μg of mAb for 1 h at 4°C. The Ab-coupled protein A-sepharose was added to pansorbin-sepharose (50 μl/lysate; Calbiochem) precleared extracts and rotated for 2 h at 4°C. Proteins bound to the Ab-coupled protein A-sepharose were precipitated by centrifugation, washed three times, boiled for 3 min at 95°C in 2xLaemmli buffer and analyzed by immunoblotting exactly as described recently (64).

Indirect immunofluorescence. For indirect immunofluorescence cells were grown on glass coverslips as already published (19). To visualize intranuclear E1A staining, cells were extracted with 0.5% Triton X-100 in CSK buffer as described by Carvalho and coworkers (8). Cells were fixed in 4% PFA at 4°C for 20 min and permeabilized in PBS, 0.5% Triton X-100 for 30 min at room temperature. After 1 h blocking in TBS-BG buffer, coverslips were treated for 1 h with the primary antibody diluted in PBS, washed three times in PBS, 0.1% Tween 20 followed by incubation with the corresponding Alexa488 (Invitrogen) or Cy3-conjugated (Dianova) secondary antibodies. Coverslips were washed three times in PBS, 0.1% Tween 20, mounted in Glow medium (Energene) and digital images were acquired with a confocal laser scanning microscope (Zeiss-CLSM-510). Images were cropped using Adobe PhotoshopCS4 and assembled with Adobe Illustrator CS4.

Quantitative RT-PCR analysis.
Subconfluent HepaRG cells were infected with wild-type virus at a multiplicity of 50 ffu/cell and harvested 24 h p.i. Total RNA was isolated with Trizol reagent (Invitrogen) as described by the manufacturer. The amount of total RNA was measured, and 1 µg of RNA was reverse transcribed using the Reverse Transcription System from Promega. To amplify specific viral genes, primers were designed as follows (18S rRNA fwd primer 5'-CGGCTACCACATCAAAGGAA-3'; 18S rRNA rev primer 5'-GCTGGAATTACCGCGGCT-3'; E2A fwd primer 5'-GAAATTACGGTGATGAACCCG-3'; E2A rev primer 5'-CAGCCTCCATGCCCCTTCTCC-3'); Quantitative reverse transcription (RT)-PCR was performed with a first-strand method in a Rotor-Gene 6000 (Corbett Life Sciences, Sydney, Australia) in 0.5-ml reaction tubes containing a 1/50 dilution of the cDNA template, 10 pmol/µl of each synthetic oligonucleotide primer and 5 µl/sample SensiMix SYBR (Bioline). The PCR conditions were as follows: 10 min at 95°C, followed by 40 cycles of 30 s at 95°C, 30 s at 62°C, and 30 s at 72°C. The average threshold cycle (CT) value was determined from triplicate reactions, and levels of viral mRNA relative to cellular 18S rRNA were calculated as described recently. The identities of the products obtained were confirmed by melting curve analysis.
Results

Ad5 E1A-13S localizes to endogenous PML in transiently transfected cells.

Although reports proposed different functions of E1A-12S and E1A-13S during adenoviral infection (83), E1A has been described to localize to PML nuclear bodies (8). In this context, we decided to express both E1A isoforms separately and visualize their localization with respect to endogenous PML bodies. Both isoforms localized to the nucleus in large amounts (Fig. 1A; g, k), whereas PML exhibited the characteristic punctate nuclear staining (Fig. 1A; f, j). Consistent with published results E1A-12S as well as E1A-13S relocalized PML bodies, causing them to appear bigger in size and lower in number (20).

Since the high amounts of intranuclear E1A render it very difficult to spot any distinct staining patterns, the cells were treated as described in Material and Methods (Indirect immunofluorescence) prior to fixation (Fig. 1B; 8). After pre-extraction, E1A-13S accumulates in several brightly stained nuclear aggregates juxtaposed to endogenous PML in ~30% of the transfected cells (Fig.1B, i-l). For the smaller E1A-12S isoform no staining juxtaposed to PML could be observed (Fig. 1B, e-h). Our observations are consistent with previous reports showing that transcriptionally active proteins often tend to associate with the nuclear matrix (65).

Ad5 E1A-13S localizes to PML nuclear bodies during adenoviral infection.

Detailed studies have revealed an astonishing amount of cross-talk between adenoviral proteins in the modulation of host cell factors, e.g. PML and PML-associated proteins. Previously published data illustrate that the viral protein E4orf3 is necessary and sufficient to disrupt the structure of cellular PML-NBs during Ad5
infection (8, 37, 52, 73). In addition, viral early E1B-55K protein has been shown to interact and functionally cooperate with PML bodies (53, 80, 85, 102, 104).

To evaluate whether other adenoviral proteins interfere with, or alter the cooperation between E1A and PML, we further analyzed localization during productive infection (Fig. 2). Cells were infected with wild type virus (H5pg4100) and virus mutants expressing E1A-12S (H5dl347) or E1A-13S (H5dl348). To exclude expression of other adenoviral proteins mediating PML interaction, viruses lacking E1B-55K (H5pm4149) or E4orf3 (H5pm4150) were included as controls.

As expected, PML was relocalized (Fig. 2a, 2f, 2j, 2n, 2r) into so-called *track-like* structures in infected cells. The virus mutant lacking E4orf3 protein (H5pm4150) was no longer able to relocalize PML bodies, although their shape was different from the punctate staining in mock-infected cells (Fig. 2a; 2v). We detected E1A colocalization with PML *track-like structures* in wild type virus (H5pg4100) as well as H5dl348-infected cells expressing only E1A-13S (Fig. 2g, 2o), whereas E1A-12S (H5dl347) is distributed much more diffusely in the host-cell nucleus (Fig. 2k). E1A also localized to PML after infection with virus lacking E4orf3 or E1B-55K (Fig. 2t, 2q). Based on these observations, we conclude that E1A-13S localizes to PML nuclear bodies independently of E4orf3 or E1B-55K expression.

Ad5 E1A-13S specifically interacts with human PML-II isoform in transiently transfected cells.

Human cells express at least seven distinguishable PML isoforms (41), of which PML-I to -VI possess a nuclear localization sequence. To ascertain whether E1A specifically interacts with different PML isoforms, human cells were transfected with
E1A-13S or E1A-12S and plasmids encoding human PML isoforms I to VI. By precipitating flag-tagged PML and subsequently staining for E1A, we detected a highly specific interaction between E1A-13S and PML-isoform II (Fig. 3D, lane 4). E1A-12S could not be co-precipitated with any PML isoform (Fig. 3B), although the steady-state levels showed equal amounts of transfected PML and E1A isoforms (Fig. 2A, 2C).

Mutational screening of E1A-13S revealed PML-II isoform interaction within CR3. Since E1A-13S differs from E1A-12S in only CR3, composed of 46 aa, we assumed that PML-II binding depends on this or adjacent regions in the E1A protein. To more precisely identify the binding domain required for E1A-13S/PML-II interaction, we constructed E1A-13S mutants with overlapping 14-16 aa deletions spanning the proposed region (Fig. 4A). Although the E1A-13S mutants had slightly altered gel migration properties, input levels of E1A-13S and PML-II were equal in our co-immunoprecipitation assays (Fig. 4B). These experiments revealed that deletion mutant no. 7 (E1A-13SΔ176-191; Fig. 4A) exhibits strongly impaired PML-II binding properties (Fig. 4C, lane 11).

To further narrow down the interaction region, a shorter deletion mutant E1A-13SΔ182-191 was constructed and tested for PML-II binding (Fig. 5A). We confirmed binding deficiency of deletion mutant E1A-13SΔ182-191 with PML-II isoform by immunofluorescence analysis and co-immunoprecipitation experiments (data not shown).
Ad5 E1A-13S interacts with endogenous PML in plasmid transfected and infected cells.

Next, we verified our observations by co-immunoprecipitation experiments with endogenous PML. We transfected human cells with E1A-12S, E1A-13S, or E1A-13SΔ182-191, or infected them with wild type virus (H5pg4100), and virus mutants expressing only E1A-12S (H5dl347), only E1A-13S (H5dl348), or no E1A protein (H5dl312) as a negative control (Fig. 5B). After precipitating endogenous PML and subsequent staining for E1A, we could detect specific interaction of endogenous PML with transfected E1A-13S as well as viral E1A in H5pg4100- and H5dl348-infected cells (Fig. 5C, lanes 3, 5 and 6). In contrast, E1A-12S, deletion mutant E1A-13SΔ182-191, and viral E1A encoded by the virus mutant lacking E1A-13S (H5dl347) could not be precipitated with endogenous PML (Fig. 5C).

In sum, interaction of E1A-13S with PML could be mapped to aa 182-191 at the end of the CR3 of E1A-13S. This binding region (aa 182-191) is highly conserved in different Ad types and has previously been identified as the variable transcription factor binding domain, or promoter-targeting domain of E1A-13S (58, 70, 97).

Ad5 E1A-13S and PML cooperation impacts viral and cellular transcription.

PML bodies have been implicated in regulating transcription (97, 107). Furthermore, it is known that several viral genomes including adenovirus localize close to PML bodies in order to start transcription and replication (38, 74). Therefore, E1A likely affects transcriptional regulation from adenoviral promoters in cooperation with PML-II.
To address this idea, we used luciferase reporter assays and transfected luciferase-dependent plasmids encoding adenoviral promoters (78) together with E1A-13S and PML-II (Fig. 6). PML-II alone was not able to stimulate transcription from Ad5 E2 early promoter, whereas E1A-13S activated luciferase activity from the viral promoter 10-fold. Furthermore, PML-II efficiently stimulated transcription from the Ad5 promoter when co-expressed with E1A-13S. This was further verified by the positive correlation between increasing levels of expressed PML-II and activated transcription at constant E1A-13S levels (Fig. 6B). As a control we also included E1A-12S and E1A-13SΔ182-191 in this reporter gene assay. We observed that neither E1A-12S nor E1A-13SΔ182-191 stimulated transcription from the adenoviral promoter in combination with equal amounts of PML-II (Fig. 6B).

Recently, Pelka et al. reported that cellular transcription factor p300 binds E1A-13S within the CR3 region, and is recruited to Ad promoters during infection (71). p300 possesses intrinsic acetyltransferase activity and is therefore an important transcriptional co-activator; it is recruited to gene promoters via its association with numerous DNA-binding transcription factors (29). PML was also found to interact with p300/CBP and regulate transcription (49, 95). In this context, we tested whether E1A-13S and PML-II affect p300 co-activator function in transcriptional regulation. We performed luciferase reporter assays with a GAL4-responsive promoter and p300 fused to a GAL4 DNA-binding domain, in combination with E1A-13S and PML-II (Fig. 7A). PML-II alone only slightly stimulated transcription from the GAL4 promoter, whereas E1A-13S enhanced p300 transcriptional activity 2-fold. Consistent with our observations above, co-expression of E1A-13S with PML-II strongly stimulated the luciferase activity from the promoter. Co-transfection of increasing...
PML-II amounts further stimulated p300-dependent transcriptional activation (Fig. 315). On the other hand, co-expression of PML-II together with E1A-13SΔ182-191 did not activate transcription from the GAL-4 promoter (Fig. 7B). Additionally, we performed the reporter gene assay shown in Figs. 6 and 7 with the other nuclear PML isoforms. Our results showed that other PML isoforms do positively affect E1A dependent transactivation although to a lesser extent compared to PML-II (Fig. 6C and 7C).

Taken together, our results on transcriptional regulation suggest that PML-II is a dose-dependent co-activator of E1A-13S-dependent transactivation. PML-II is not only able to modulate transcription from Ad5 promoters in combination with E1A-13S, but also stimulates cellular gene expression by affecting key cellular co-activators such as p300.

**PML-II positively regulates adenovirus progeny production in human cells.** To reveal the effect of PML-II on the production of adenoviral progeny, we determined virus growth in HepaRG cell lines in which endogenous PML was knocked-down (HALP cells) and sh-RNA resistant PML-II isoform was reconstituted (HALP PML-II) (12). In accordance with recent reports, PML-knockdown showed a modest effect on adenovirus replication compared to the parental cell line (80, 92). However, reconstitution of the single isoform PML-II enhanced virus yield several-fold compared to the parental cell line (Fig. 8). Consistent with the data obtained from the reporter assays, this strongly indicates that PML-II is a positive regulator of Ad5 replication in human cells. To further test the positive effect of PML isoforms we measured early gene expression in an abortive infection in PML null mouse embryonic fibroblasts (MEF) to confirm the data obtained from the reporter gene...
experiments. In this context, we performed time course experiments in PML -/- mouse embryonic fibroblasts (MEF) compared to PML +/- MEF cells. We observed a delay in the protein expression of E2A (Fig. 9A) as well as reduced E2A mRNA expression in MEF cells without PML (Fig. 9B).

*Transcriptional co-activation by PML does not depend on its functional SIM.*

PML forming PML-NBs, its dynamic behavior, as well as its mode of function is mainly based on SUMOylation of the PML protein itself (17, 82, 106). The PML-SIM is required to form PML-NBs when exogenously expressed in PML -/- cells, and enables PML to interact non-covalently with SUMOylated proteins including PML itself (82). In line with these observations, we were interested in whether the PML-SIM, necessary for interacting with other SUMOylated factors in the PML-NBs, plays a role in transcriptional activation of Ad promoters by PML-II together with E1A-13S (Fig. 10A). Therefore, we generated a PML-II mutant with a non-functional SIM. Interestingly, this mutant stimulated E1A-13S-dependent transcription from the Ad5 E2 early promoter more efficient than PML-II wild type (Fig. 10B). We also tested whether the PML-II-SIM mutant affected E1A-13S binding properties. PML-II-SIM and wild type PML-II were expressed at equal amounts (Fig. 10C) and co-immunoprecipitation experiments showed no differences in binding capabilities between PML-II-wild type and PML-II-SIM (Fig. 10D, lanes 3 and 5).
Discussion

PML bodies are mainly considered to be part of an intracellular anti-viral defense mechanism, activated by interferon upon viral infection (22, 27, 51, 90). Nevertheless, there is also evidence for a pro-viral role of PML bodies (21). Here, we show for the first time an adenoviral protein taking direct advantage of PML; E1A-13S apparently physically interacts with the PML-II isoform to positively affect E1A-dependent transcriptional activation. Since neither E1A nor PML possess DNA binding activity, our data support the idea that PML activates transcription through stabilizing co-activator/transcription factor complexes. Based on our observations that PML-II enhances p300 co-activator function, it is also likely that PML acts as a platform for E1A-13S to interact with other co-activators or transcription factors.

PML isoforms that do not interact with E1A-13S in co-immunoprecipitation experiments do activate E1A-13S-dependent transcription to some extend (Fig. 6C and 7C). So far, it is known that PML isoforms form homo- and heterodimers via their RBCC/TRIM motif (41). As the reporter gene assays were not performed in PML knockout cells, there is endogenous PML-II present, which could heterodimerize with the other PML isoforms. On the other hand it is also possible that the interaction of E1A and PML-II is more stable compared to the other PML isoforms and that those weak interactions could not be monitored in our co-immunoprecipitation assays due to a stringent lysis buffer.

It was already known that HPV (human papillomavirus) infection is positively influenced by PML expression (13). HCMV (human cytomegalovirus) and HSV-1 (human herpesvirus type 1) genome transcription exclusively takes place at PML bodies (38, 40, 60). During lytic infection, HSV-1 recruits several cellular DNA repair
factors from PML bodies into viral replication centers to support viral replication (55, 99, 100). SV40 (simian polyoma virus type 40) transcription and replication preferentially occurs in the vicinity of PML NBs (89) and similar observations were made for human polyomaviruses (42, 84). These reports suggest that PML-NBs might be a “host-cell depot” for transcription or DNA repair factors.

We currently favor the model that PML-NBs possess antiviral properties due to the large number of repressive proteins localizing to these compartments, such as Daxx or p53 (33, 54, 69). Therefore, during evolution adenoviruses have apparently acquired a mechanism to counteract this PML-NB function, disrupting the integrity of PML-NBs by expressing early viral E4orf3, which causes PML-NB components to redistribute into so-called track-like structures (8, 15). Consequently, repressive factors would become accessible for targeting by further viral factors, such as Ad5 E1B-55K, that localize to PML-tracks (15, 53). Recently, our group showed that the constitutive PML-NB protein Daxx represses Ad5 gene expression and productive infection (80). This is counteracted by capsid protein pVI-dependent Daxx relocalization from the nuclear bodies in immediate early times of infection, followed by E1B-55K-dependent proteasomal degradation (78, 80).

In addition to Daxx (79, 85), E1B-55K physically interacts with two different PML isoforms, PML-IV and V (102). Since PML-IV is the only isoform described to recruit or modulate p53 (25), the interaction between E1B-55K and PML-IV might be a key regulatory event to modify or repress p53 functions. Together, these observations imply that adenoviral proteins specifically target and counteract repressive proteins from PML bodies, or take advantage of PML and associated factors as discussed...
above, in order to regulate cellular processes to benefit viral transcription/replication.

So far E4orf3 was the only adenoviral protein known to physically interact with PML-II (37). Although our data show that E1A-13S interacts with PML-II independently of E4orf3, the fact that both adenoviral proteins target the same PML isoform provides evidence for cooperation between E1A, E4orf3 and PML-II during productive adenoviral infection, although we cannot observe an effect of adding E4orf3 expression vector to the luciferase assays shown in Figures 6 and 7 (data not shown).

Our observation that mutation of the SIM in PML-II further enhanced E1A-dependent transactivation supports our model that Ad5 selectively benefits from PML-NB functions. The PML-SIM has been proposed to mediate non-covalent interactions with other PML isoforms and SUMOylated proteins (56, 82). Our data imply that the co-activator properties of PML do not necessarily depend on its localization to PML bodies. Thus, it is tempting to speculate that protein interactions within PML bodies, mediated by the SIM, may inhibit transcriptional stimulation by PML itself.

However, the enormous amount of PML-associated proteins may offer additional mechanisms to further understand E1A-13S/PML-II functional interaction. Nevertheless, our data support the idea that viral factors targeting PML not only represents a means of counteracting host mechanisms, but also appears to be required and beneficial for productive viral infection.
Acknowledgements

We thank Roger Everett, Philippe Gripon, Roger Grand, Thomas Shenk for providing reagents, and greatly appreciate the critical comments and advise from Andrew Turnell, Thomas Sternsdorf, Hans Will and Michael Nevels. The Heinrich Pette Institute, Leibniz Institute for Experimental Virology is supported by the Freie und Hansestadt Hamburg and the Bundesministerium für Gesundheit (BMG). Part of this work was supported by grants from the Erich und Gertrud Roggenbuck Stiftung, the Horst Müggenburg Stiftung, and the Wilhelm Sander-Stiftung to SS and TD.
References


Figure Legends

Fig. 1. E1A-13S colocalizes with endogenous PML in transiently transfected cells.

(A) HepaRG cells were transfected with 3 µg of pE1A-12S or pE1A-13S, fixed with 4% PFA 48 h post transfection and double labeled with mAb M-58 (α-E1A) and pAb NB 100-59787 (α-PML). (B) HepaRG cells were extracted with cytoskeleton buffer prior to fixation with 4% PFA. In A and B primary Abs were detected with Cy3 (α-PML; green) and Alexa488 (α-E1A; red) conjugated secondary Ab. For nuclear staining the DNA intercalating dye DRAQ5 (Biostatus) was used. Representative E1A (Ac, g, k; Bc, g, k) and α-PML (Ab, f, j; Bb, f, j) staining patterns of at least 50 analyzed cells are shown. Overlays of single images (merge) are shown in Ad, h, i; Bd, h, i (magnification x 7600).

Fig. 2. E1A-13S colocalizes with endogenous PML in infected cells. Human hepatocytes (HepaRG) were infected with wild type (H5pg4100) or mutant viruses (H5dl347, H5dl348; H5pm4149, H5pm4150) at a multiplicity of 50 ffu/cell and fixed with 4% PFA 24 h p.i. The cells were extracted with cytoskeleton buffer prior to fixation and double labeled with mAb M-58 (α-E1A) and pAb NB 100-59787 (α-PML). Detection of primary Abs and nuclear staining was performed as in Fig. 1. Representative α-E1A (red; c, g, k, o, s, w) and α-PML (green; b, f, j, n, r, v) staining patterns of at least 50 analyzed cells are shown. Overlays of the single images (merge) are shown in d, h, i (magnification x 7600).

Fig. 3. E1A-13S binds a specific PML isoform in transiently transfected H1299 cells.

Subconfluent H1299 cells were transfected with 3 µg of pE1A-12S-wild type or pE1A-
13S- wild type and 5 µg of different lentiviral constructs encoding N-terminal flag-tagged human PML isoforms I-VI, harvested after 48 h, to prepare total-cell extracts. Immunoprecipitation of flag-PML was performed using mAb flag-M2 (α-flag), and proteins resolved on 10% SDS-PAGE were visualized by immunoblotting. Input levels in total cell-lysates (A, C) and coprecipitated proteins (B, D) were detected using mAb 610 (α-E1A), mAb flag-M2 (α-flag) and mAb AC-15 (α-β-actin). Molecular weight in kDa is indicated on the Left, while the relevant proteins are labeled on the Right. Note that heavy chains (IgH) are detected at 55kDa in B and C.

Fig. 4. Mapping experiments identified an E1A mutant defective in binding PML-II. (A) Overlapping deletions of 14-16 aa spanning CR3 and adjacent regions are shown below the schematic representation of E1A-12S and E1A-13S protein structures. Detailed amino acid deletions of each mutant are listed on the Right. (B, C) Subconfluent H1299 cells were transfected with 3 µg of pE1A-13S- wild type or pE1A-13S deletion mutants and 3 µg of pPML-II, harvested after 48 h, before preparing total-cell extracts. Co-immunoprecipitation assays were performed as described in Fig. 3. Note the different E1A-13S deletion mutants show different mobilities. Molecular weights in kDa are indicated on the Left, appropriate proteins on the Right.

Fig. 5. Interaction with PML-II depends on a highly conserved transcription factor binding region within CR3. (A) The schematic representation of E1A-12S and E1A-13S with the enlarged interaction region depicted below. Mapped is the the newly constructed PML-II/E1A-binding mutant 13SΔ182-191 with a shorter deletion as the
previously identified 13SΔ176-191. (B, C) Subconfluent H1299 cells were transfected with 3 µg of pE1A-12S- wild type, pE1A-13S and pE1A-13S 182-191, or infected with wild type virus (H5pg4100) or virus mutants (H5dl312, H5dl347, H5dl348). The cells were harvested 48 hours after transfection or 24 h. p.i. and total-cell extracts were prepared. Immunoprecipitation of endogenous PML was performed using pAb NB100-59787 (α-PML), proteins were resolved on 10% SDS-PAGE and visualized by immunoblotting. Steady-state expression levels of total cell-lysates (input) and coprecipitated proteins (IP) were detected using mAb 610 (α-E1A), pAb NB100-59787 (α-PML) and mAb AC-15 (α-β-actin). Molecular weights in kDa on the Left, corresponding proteins on the Right.
Fig. 6. PML stimulates E1A-13S-dependent transcriptional activation of adenoviral E2 early promoter. (A) Schematic representation of the luciferase reporter assay: the luciferase gene is under the control of the Ad5 promoter, which is bound and activated by a complex of E1A-13S and PML-II. (B) H1299 cells were transfected with 0.2 µg of pRenilla-Luc, 0.5 µg pGL-E2early-promoter, 0.2 µg pE1A (E1A-12S, E1A-13S, E1A-13SΔ182-191) and increasing amounts of pPML-II in the combinations indicated (+). 24 h post transfection total cell extracts were prepared and luciferase activity was determined. The mean and standard deviations are presented for three independent experiments. (C) H1299 cells were transfected with 0.2 µg of pRenilla-Luc, 0.5 µg pGL-C3G5-luc, 0.5 µg pG4-p300, 1 µg pE1A (E1A-13S, 13SΔ182-191) and 1.5 µg pPML-I-VI in the combinations indicated. 24 h post transfection total cell extracts were prepared and luciferase activity was determined. The mean and standard deviations are presented for three independent experiments.

Fig. 7. E1A-13S and PML cooperate to stimulate p300 transcriptional coactivation. (A) Schematic presentation of the luciferase reporter assay: the luciferase gene is under the control of a promoter containing 5 GAL4 sequences, which is bound and activated by a complex of GAL-p300, E1A-13S and PML-II. (B) H1299 cells were transfected with 0.2 µg of pRenilla-Luc, 0.5 µg pGL-C3G5-luc, 0.5 µg pG4-p300, 1 µg pE1A (E1A-13S, 13SΔ182-191) and increasing amounts of pPML-II in the combinations indicated (+). 24 h post transfection total cell extracts were prepared and luciferase activity was determined. The mean and standard deviations are presented for three independent experiments. (C) H1299 cells were transfected with 0.2 µg of pRenilla-Luc, 0.5 µg pGL-C3G5-luc, 0.5 µg pG4-p300, 1 µg pE1A-13S and 2
µg pPML-I-VI in the combinations indicated. 24 h post transfection total cell extracts were prepared and luciferase activity was determined. The mean and standard deviations are presented for three independent experiments.

**Fig. 8.** PML-II positively regulates adenovirus progeny production in human cells.

Parental HepaRG, HALP and HALP EYFP–PML-II cells were infected with wild-type H5pg4100 at a multiplicity of 50 ffu/cell. Viral particles were harvested 48 h postinfection, and virus yield was determined by quantitative E2A-72K immunofluorescence staining on 293 cells.

**Fig. 9.** Ad5 E2A is delayed in an abortive infection in PML null mouse embryonic fibroblasts Suppl. Fig. 3. (A) Subconfluent parental MEF (PML +/+ ) or PML knock-out MEF (PML -/- ) cells were infected with wild type virus H5pg4100 at a multiplicity of 50 ffu/cell. The cells were harvested 24 h p.i., total RNA was extracted, reverse transcribed, and quantified by RT-PCR analysis using primers specific for E2A. The data were normalized to 18S rRNA levels. (B) Subconfluent parental MEF (PML +/+ ) or PML knock-out MEF (PML -/- ) cells were infected with wild type virus H5pg4100 at a multiplicity of 50 ffu/cell. The cells were harvested 24, 48 and 72 h. p.i. and total-cell extracts were prepared. Steady-state expression levels of total cell-lysates were detected using mAb 610 (α-E1A), mAb B6 (α-E2A), mAb clone 36.1-104 (α-PML) and mAb AC-15 (α-β-actin). Molecular weights in kDa on the Left, corresponding proteins on the Right.
Fig. 10. SIM of PML is not important for stimulating E1A-13S-dependent transcriptional activation. (A) The schematic representation of PML-II isoform showing the SIM amino acid sequence. Shown is the newly constructed PML-II-SIM construct with introduced mutations. (B) H1299 cells were transfected with 0.2 µg pRenilla-Luc, 0.5 µg pGL-E2early-promoter, 0.2 µg pE1A-13S, 1.5 µg pPML-II and pPML-II-SIM in the combinations indicated (+). 24 h post transfection total cell extracts were prepared and luciferase activity was determined. The mean and standard deviations are presented for three independent experiments. (C, D) Subconfluent H1299 cells were transfected with 3 µg of pE1A-13S and 5 µg of pPML-II or pPML-II-SIM, harvested after 48 hours and total-cell extracts were prepared. Co-immunoprecipitation assays were performed as described in Figure 3. (C) Input levels in total cell-lysates and (D) coprecipitated proteins. Molecular weights in kDa are on the Left, while corresponding proteins are indicated on the Right.
Figure 1
Berscheminski et al.

A

mock  DRAQ5

PML  E1A  merge

E1A-12S  DRAQ5

PML  E1A  merge

E1A-13S  DRAQ5

PML  E1A  merge

B

mock  DRAQ5

PML  E1A  merge

E1A-12S  DRAQ5

PML  E1A  merge

E1A-13S  DRAQ5

PML  E1A  merge
Figure 2
Berscheminski et al.
Figure 3
Berscheminski et al.

A

input

+ pAd5 E1A-12S

kDa

β-actin

E1A-12S

exogenous flag-PML

1 2 3 4 5 6 7 8

B

IP α-flag (M2)

+ Ad5 E1A-12S

IgH

E1A-12S

1 2 3 4 5 6 7 8

C

input

+ pAd5 E1A-13S

kDa

β-actin

E1A-13S

exogenous flag-PML

1 2 3 4 5 6 7 8

D

IP α-flag (M2)

+ Ad5 E1A-13S

IgH

E1A-13S

1 2 3 4 5 6 7 8
Figure 4
Berscheminski et al.

A

0 50 100 150 200 250 aa

E1A-12S (243 aa)
CR1 CR2 CR4

E1A-13S (289 aa)
CR1 CR2 CR3 CR4

PVSMNLVPEDLCTHCAGPFSDDEEDEGSFVLEHHPGHGRSGYHRNTGFBFVDMCSLCPMTCDMFVYSYPVEPEFPEPAPRTRFPKMAPALLRRTSPVSR

Δ109-124
Δ132-146
Δ121-135
Δ143-157
Δ154-168
Δ166-180
Δ176-191
Δ188-202
Δ198-212
Δ209-223

B

input + flag-PML II

kDa

55
36
130
95

β-actin

E1A-13S

flag-PML II

C

IP α-flag M2 + flag-PML II

kDa

55
36

E1A-13S
Figure 5
Berscheminski et al.

A

\[
\begin{array}{c}
\text{CR1} \quad \text{CR2} \quad \text{CR3} \quad \text{CR4} \\
\end{array}
\]

\[
\begin{array}{c}
\text{E1A-12S (243 aa)} \\
\text{Δ182-191} \\
\text{E1A-13S (289 aa)}
\end{array}
\]

\[
\begin{array}{c}
\text{E1A (short exposure)} \\
\text{E1A (long exposure)}
\end{array}
\]

B

\[
\begin{array}{c}
\text{input} \\
\text{empty vector} \\
\text{E1A-12S wt} \\
\text{E1A-13S wt} \\
\text{Δ182-191} \\
\text{ΔE1A (AE1-A13S)} \\
\text{ΔE1A (AE1-A12S)} \\
\end{array}
\]

C

\[
\begin{array}{c}
\text{IP α-PML (endogenous)} \\
\text{kDa} \\
\text{55} \\
\text{E1A} \\
\text{Δ182-191} \\
\text{E1A-13S (289 aa)} \\
\text{E1A-12S (243 aa)} \\
\text{CR1 CR2 CR3 CR4} \\
\text{Δ182-191} \\
\end{array}
\]

\[
\begin{array}{c}
\text{endogenous} \\
\text{PML} \\
\text{β-actin} \\
\text{E1A} \\
\end{array}
\]

\[
\begin{array}{c}
\text{Δ182-191} \\
\text{50 100 150 200 2500} \\
\text{aa} \\
\end{array}
\]
Figure 6
Berscheminski et al.

A

B

C

relative Firefly-luciferase activity

Renilla-Luc
E2early promoter
E1A-13S
E1A-12S
E1A-13SΔ182-191
PML II

relative Firefly-luciferase activity

Renilla-Luc
E2early promoter
E1A-13S
PML II
PML I
PML III
PML IV
PML V
PML VI

0,2
0,2
0,2
0,2
0,2
0,2
0,2
1,5
1,5
1,5
1,5
Figure 7
Berscheminski et al.

A

B

C

relative Firefly-Luciferase activity

0 1 2 3 4 5 6 7 8 9 10 11

1 2 3 4 5 6 7 8 9 10 11

+ + + + + + + + + +

C3G5 GAL4-p300 E1A-13S

0,5 1 1 2 2

PML II PML III PML IV PML V

+ + + + + + + + + +

Renilla-Luc

+ + + + + + + + + +

GAL4-p300 E1A-13S

1 1 1 1 1 1

0,5 1 2 2

PML II PML III PML IV PML V

+ + + + + + + + + +

E1A-13SΔ182-191
Figure 8
Berscheminski et al.

Hep par.
HALP
HALP
PML-II

virus yield (FFU/cell)

0
200000
400000
600000
800000
1000000
Figure 9

Berscheminski et al.

A

<table>
<thead>
<tr>
<th>MEF PML +/-</th>
<th>MEF PML +/-</th>
</tr>
</thead>
<tbody>
<tr>
<td>mock</td>
<td>24 hpi</td>
</tr>
<tr>
<td>mock</td>
<td>24 hpi</td>
</tr>
</tbody>
</table>

- H5pg4100
- β-actin
- endogenous mouse PML
- E2A

B

<table>
<thead>
<tr>
<th>MEF PML +/-</th>
<th>MEF PML +/-</th>
</tr>
</thead>
<tbody>
<tr>
<td>mock</td>
<td>24 hpi</td>
</tr>
<tr>
<td>mock</td>
<td>24 hpi</td>
</tr>
</tbody>
</table>

relative E2A mRNA expression

10

8

6

4

2

0

MEF PML +/-
Figure 10
Berscheminskii et al.

A

Exon 1-6 | NLS | SIM
PML II  RBCC | NLS | SIM  829 aa
V V V I S S S
G G G I S S S

B

relative Firefly-luciferase activity

C

input + flag-PML II + flag-PML II-SIM

kDa

55
130
95

D

IP α-flag (M2) + flag-PML II + flag-PML II-SIM

kDa

55

<table>
<thead>
<tr>
<th>Renilla-Luc</th>
<th>E2early promoter</th>
<th>H5pg4100 MOI 50</th>
<th>E1A-13S</th>
<th>PML II</th>
<th>PMLII-SIM</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>β-actin</th>
<th>E1A-13S</th>
<th>flag-PML II</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H5pg4100 MOI 50</th>
<th>E1A-13S</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 2 3 4 5</td>
<td>+</td>
</tr>
<tr>
<td>1 2 3 4 5</td>
<td>+</td>
</tr>
<tr>
<td>1 2 3 4 5</td>
<td>+</td>
</tr>
<tr>
<td>1 2 3 4 5</td>
<td>+</td>
</tr>
<tr>
<td>1 2 3 4 5</td>
<td>+</td>
</tr>
</tbody>
</table>